Q&A with Avacta CEO, Alastair Smith

08:13, 25th February 2021

Avacta (AVCT FOLLOW) CEO, Alastair Smith, discusses their recent business update. He covers their two platform technologies along with their lateral flow antigen test and 2021 milestones

1.  Summary of Avacta’s two breakthrough platforms (48 seconds)
2.   Rapid lateral flow antigen tests (7mins 18secs)
3.   pre|CISION - tumour targeted chemotherapy & phase 1 trial of Pro-doxorubicin (19mins 58sec)
4.   Affimer bio/immuno-therapies (25mins 53secs)
5.   3rd party licensing initiatives (31mins 8secs)
6.   Key milestones over next 12 months (36mins 23secs)

Disclaimer & Declaration of Interest

The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.

Login or register to post comments

Recent Articles